Top Tweets for #Gu26
I love following @katy_beckermann on @X & wonderful to see her deliver comments live at #KCRS26, summarizing key updates from #GU26. Great takeaways from #LS022 & #LS011 (@DrChoueiri @tompowles1 @motzermd) & beautiful summary tables I encourage you to all look at.
@drenriquegrande @SScagliarini_ There is an interesting overlap in RC refusal and RT refusal at the certain point, in particular after deep response to systemic therapy. Yet the #Sunrise2 data were impressive in favor of ChRT #GU26
Thanks for highlighting
JUST IN: @US_FDA approves combo HIF2 inhibitor Belzutifan + PD1 inhibitor Pembrolizumab in adjuvant Kidney Cancer. Approval based on LS022 trial co-led with @tompowles1 presented @ASCO #GU26 adding another approval to @NobelPrize story with @kaelin_lab @DanaFarber @DanaFarber_GU !
Onward ! Great day for patients !
#HIF2 #oncology #labubu
https://t.co/hLVbj7QwlH
https://t.co/cz81izpdxT
🚹 Updated 15-year phase III ASCENDE-RT data showed no statistically significant OS difference between prostate brachytherapy boost and EBRT boost in localized intermediate-/high-risk #prostatecancer.
🗣️ Presented by Dr. Scott Tyldesley at #GU26 | #PCSM
🔗 https://t.co/tdodLslLFa
Great to moderate this stellar panel @MattGalsky @sonpavde @siadaneshmand @UroDocAsh @BradMcG04 @Onco_Nexus @ASCO #GU26
@MattGalsky highlights how the standard of care in MIBC is shifting, and what the KEYNOTE-B15 data could mean for treatment decisions in practice. This roundtable featuring @siadaneshmand, @sonpavde, @PGrivasMDPhD , @BradMcG04 , & @UroDocAsh looks at where perioperative EV plus pembrolizumab may fit, along with the patient selection and implementation questions clinicians are now facing.
-- https://t.co/7pyTEN7UAx
Stay up to date with treatment advances in #RCC! Drs. @montypal, @PBarataMD, and @crisuarez08 use practice case discussions to illustrate the real-world application of emerging data: https://t.co/pWgPmpImaK #GU26 #Oncology #MedEd
🔬 Belzutifan + lenvatinib may reshape post–IO care in advanced RCC.
In phase III LITESPARK-011, the combo improved PFS (14.8 vs 10.7 months), ORR vs cabozantinib.
➡️ Trend toward OS benefit.
🗣️ Presented by @motzermd of @MSK_DeptOfMed at #GU26
https://t.co/PRDKdDovbo
After returning from @ASCO #GU26, @SFreedlandMD (@CedarsSinai) sat down with @CaPsurvivorship (@DanaFarber) to discuss key trials highlighting progress in #ProstateCancer care, including novel treatment strategies and combination therapies.
Watch here! https://t.co/EOuMwxdHk4
🆕 The April issue of The ASCO Post is LIVE, featuring highlights from #MBCC26, #GI26, #GU26; perspectives on #prostatecancer screening; an interview with @VanAllenLab on #AI in #cancerresearch; and MORE!
Read the full issue 👉 https://t.co/5fObByvTBN
@montypal @PGrivasMDPhD @BladderCancerUS @KidneyCancer @PCFnews @Prof_Nick_James @neerajaiims @TiansterZhang @NazliDizman @cityofhope The attendance stats he showed beat #GU26!
Almost certainly because of speaker line up that included superstars @montypal @neerajaiims @PGrivasMDPhD @Prof_Nick_James ⭐️⭐️⭐️
🚨⭐️ @ASCO #GU26 Insights: Evolving #BladderCancer Strategies w/@ziremozay @huntsmancancer
🔷Periop EV + pembro delivers strong pCR & survival in #MIBC
🔶BCG + IO in high-risk #NMIBC
🔷ADC toxicity tips
#OncTwitter #gusm #MedTwitter
📍Full Summary 👇
https://t.co/zngpFEUKU4
How are you approaching modern therapies in #RCC? Learn how to apply emerging evidence and tailor treatment across the disease spectrum. Drs. @montypal, @PBarataMD, and @crisuarez08 discuss it all at #GU26 🔗 https://t.co/pWgPmpImaK #Oncology #MedEd
#ProstateCancer treatment is evolving fast and improving outcomes! Watch as leading experts, Drs. Karim Fizazi, @SFreedlandMD, and Matthew R. Smith, apply the latest clinical evidence to real-world patient cases: https://t.co/04QdE0h9oK #GU26 #MedEd
☕️Morning Insights w/@Charbel_matar1
@ASCO #GU26-🔑 Updates in #Bladder, #Prostate, and #KidneyCancer
•EV + pembro pushing higher pCR rates in MIBC
•PSMA PET reshaping prostate staging + treatment
#OncTwitter #MedTwitter #FOAMed @GWCancer
Full 📝👇
https://t.co/FHAVDAaHkf
WATCH:
@DrRanaMcKay of @UCSanDiego discusses findings from the phase 4 OPTYX trial of real-world relugolix in patients with advanced prostate cancer that were presented during the 2026 Genitourinary Cancers Symposium. #GU26 #oncology #medtwitter
Great chance to catch up with @ChrisSweens1 at #GU26 about his tour-de-force plenary overview of evolution in initial management of advanced prostate cancer. Thanks @urotoday!
https://t.co/i0ZUygRq0r
⭐️Treatment Algorithm: #KidneyCancer
w/@OncBrothers @katy_beckermann
Topics 🗣️:
🔷Early #RCC
🔶mRCC
🔷Sequencing
🔶@ASCO #GU26 updates
🔷LITESPARK-022+ LITESPARK-011
#OncTwitter #Oncology #MedTwitter #gusm #FOAMed #MedEd #MedX
🔗Watch Full Video👇
https://t.co/w7lfMo1W6o
🩸 ctDNA continues to expand its role in #bladdercancer:
➕ Combining cystoscopy + ctDNA improved detection accuracy to 95%
➡️ Potential to identify patients who can safely avoid cystectomy
🗣️ Presented by Matthew R. Zibelman, MD at #GU26
🔗 https://t.co/c7mcFRfJdR
April is testicular cancer awareness month and at #GU26, @DaliaKaakourMD highlights #ctDNA as a sensitive surveillance tool in #TesticularCancer 🧬✅
Watch the insights 🎥 https://t.co/aVY1NzvTb2
#Oncology #gusm
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
241.2M followers
Barack Obama
@barackobama
119.1M followers
Cristiano Ronaldo
@cristiano
112.7M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98.2M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91.4M followers
KATY PERRY
@katyperry
88.9M followers
Taylor Swift
@taylorswift13
82.8M followers
Lady Gaga
@ladygaga
74.3M followers
Virat Kohli
@imvkohli
71.7M followers
Kim Kardashian
@kimkardashian
70.4M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
64.6M followers
Bill Gates
@billgates
64.5M followers
The Ellen Show
@theellenshow
62.4M followers
Selena Gomez
@selenagomez
61.9M followers
CNN
@cnn
61.8M followers
X
@x
60.8M followers